Biogen to Acquire Apellis Pharmaceuticals for Approximately $5.6 Billion

Biogen Acquires Human Immunology Biosciences for up to $1.8B

May 22, 2024

Biotechnology

Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline

June 2, 2025

Pharmaceuticals

Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.

Biogen Acquires Reata Pharmaceuticals

July 28, 2023

Biotechnology

Biogen Inc. agreed to acquire Reata Pharmaceuticals, Inc. for $172.50 per share in cash, representing an enterprise value of approximately $7.3 billion. The acquisition adds Reata's FDA-approved SKYCLARYS (omaveloxolone) for Friedreich's ataxia to Biogen's rare disease portfolio and is expected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025; the transaction was anticipated to close in Q4 2023.

AbbVie Acquires Nimble Therapeutics in $200 Million Deal

January 23, 2025

Biotechnology

AbbVie announced and later completed the acquisition of Nimble Therapeutics for $200 million in cash at closing, plus interim funding and potential development milestone payments to Nimble shareholders. The deal adds Nimble’s preclinical oral peptide IL23R inhibitor for psoriasis/IBD and its proprietary peptide synthesis, screening, and optimization platform to strengthen AbbVie’s immunology pipeline and R&D capabilities.

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Pharmaceuticals

AbbVie entered into a definitive agreement to acquire ImmunoGen, including its flagship ADC therapy ELAHERE (mirvetuximab soravtansine-gynx), in a deal valued at approximately $10.1 billion. The transaction is expected to close in mid-2024, subject to ImmunoGen shareholder approval, regulatory approvals, and other customary closing conditions.